cmi101

Charles Intenzo, MD

Contact Dr. Intenzo

132 South 10th Street
Suite 861, Main Building
Philadelphia, PA 19107

(215) 955-7871
(215) 923-0268 fax

Most Recent Peer-reviewed Publications

  1. VAPC-1 Targeted64Cu-TP3805 kit preparation and its evaluation
  2. Provider Distribution Changes in Dual-Energy X-Ray Absorptiometry in the Medicare Population Over the Past Decade
  3. N-Acetyl cysteine may support dopamine neurons in Parkinson's disease: Preliminary clinical and cell line data
  4. VPAC1 targeted64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man
  5. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
  6. <sup>90</sup>Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
  7. Clinical comparison of99mTc exametazime and123I ioflupane SPECT in patients with chronic mild traumatic brain injury
  8. Effectiveness of PET/CT in the preoperative evaluation of neck disease
  9. Altered drainage patterns in patients with melanoma and previous axillary dissection
  10. VPAC1 receptors for imaging breast cancer: A feasibility study
  11. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
  12. Recent reimbursement changes and their effect on hospital and private office use of myocardial perfusion imaging
  13. Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer
  14. SNM practice guideline for parathyroid scintigraphy 4.0
  15. Positron Emission Tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma
  16. Imaging of the thyroid in benign and malignant disease
  17. Subclinical hyperthyroidism: Current concepts and scintigraphic imaging
  18. A phase i trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: First report of a completed study
  19. FDG-PET staging and importance of lymph node SUV in head and neck cancer
  20. Lymphoscintigraphy in cutaneous melanoma: An updated total body atlas of sentinel node mapping